vimarsana.com
Home
Live Updates
Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Dif
Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Dif
Dr Bagley on the ACTION Trial of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas
Stephen Bagley, MD, MSCE, discusses the phase 3 ACTION trial evaluating ONC201 in H3K27M-mutant diffuse midline gliomas.
Related Keywords
United States ,
Stephen Bagley ,
University Of Pennsylvania Hospital ,
Pennsylvania Hospital ,
Penn Medicine ,
Phase 3 Action Trial ,
Onc201 I ,
H3k27m Mutant Diffuse Midline Gliomas ,
Nct05580562 ,